Can-Fite BioPharma
Can-Fite is an Israeli company developing adenosine A3 receptor agonists; namodenoson is in phase 3 as a second-line treatment for liver cancer in patients with poor liver function.
Overview
Can-Fite BioPharma, founded in 1994 and based in Petah Tikva, Israel, develops small molecules that act on the adenosine A3 receptor, which is overexpressed in tumour and inflamed cells. Namodenoson is in a phase 3 trial in hepatocellular carcinoma with Child-Pugh B liver function, a group with few options, and piclidenoson is tested in psoriasis. Its trials are registered on ClinicalTrials.gov under Can-Fite as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyAscletis Pharma
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyGC Cell
Shares Pivotal (registrational) trial, Clinical trial, Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.